at pH 3.5 revealed a single spot with an Rf of 0.80 com-

Amino acid composition of the hexadecapeptide following acid hydrolysis was Asp(1.1), Thr(0.9), Ser(1.0), Glu(2.0), Val(1.0), Ile(1.0), Leu(4.2), Tyr(0.9), Lys(1.0), His(0.9), Arg(1.9). Complete removal of protecting groups was assessed by total enzymatic hydrolysis8 revealing no unnatural amino acids and peptide extinction coefficient of 1690 with maximal absorbance at 277 nm.

The quantitative amount of truncated or failure sequences in the purified hexadecapeptide was determined by complete sequence analysis, a stringent technique of assessing purity^{11,12}. The presence of deletion peptides for truncated sequences never exceeded 6% (cycle 8 of the degradation) on a molar basis, as evaluated by gas-liquid chromatogra phy^{13}

The dose-response relationships of the synthetic hexadecapeptide and ubiquitin are presented for prothymocyte-tothymocyte differentiation (figure 1), CR B cell-to-CR B cell differentiation (figure 1) and determination of intracellular cyclic AMP levels in sarcoma 180 cells (figure 2). The activity of the synthetic hexadecapeptide paralleled that of ubiquitin in each assay, showing approximately 40% activity by comparison with ubiquitin in each assay. For each assay the synthetic hexadecapeptide showed, like ubiquitin, a concentration range with maximal activity and, at higher concentrations, inhibition. The activity of the synthetic hexadecapeptide fragment of ubiquitin paralleled that of the parent molecule in all 3 assays. By contrast thymopoietin induces selective T cell differentiation in vitro⁴ and a synthetic tridecapeptide fragment of thymopoientin (residues 24-41) also induced selective T cell differentiation in vitro, with no induction of CR⁻ to CR⁺ B cell differentiation 15,16. Additionally, the synthetic tridecapeptide segment of thymopoietin, like thymopoietin itself, produced impaired neuromuscular transmission in mice¹⁷, an effect not caused by ubiquitin or the synthetic hexadecapeptide fragment of ubiquitin (data not shown).

Thus the synthetic peptide fragments of ubiquitin and thymopoletin showed contrasting biological activities, each having the biological characteristics of the parent molecules. We infer that each contains the amino acid sequence of the parent molecule involved in biological activity and that the putative epinephrin-mimetic active site of ubiquitin is present within the COOH-terminal 16 amino acids of the 74 amino acid sequence of ubiquitin and does not require the full tertiary structure of ubiquitin for biological activity in the assays studied. Yet there is rigorous evolu-

tionary conservation of the entire amino acid sequence of ubiquitin, with complete identity between cattle and man¹⁸ and close similarity of the NH₂-terminal sequence between these mammalian ubiquitins and ubiquitin isolated from the higher plant celery⁴. This suggests that there are constraints on amino acid substitutions in ubiquitin that are unrelated to the formation of an active site comprising an amino acid sequence capable of stimulating adenylate cyclase through β -adrenergic receptors. Thus, ubiquitin almost certainly has other vital function(s) (possibly nuclear^{5,6}) which have contributed to its extraordinary evolutionary conservation in living cells, but which have not yet been detected in our biological assays.

- 1 Address for reprint requests: Department of Physiology and Biophysics, University of Illinois Medical Center, Post Office Box 6998, Chicago (Illinois 60680).
- Acknowledgments. We thank Dr Geoffrey Tregear for helpful suggestions for the synthesis strategy, Dr Jim Burton for guidance with the methods for establishing peptide purity, and Ronald King, Miriam Miller, Jeanette Dilley and Linda Townley for excellent technical assistance. This work was supported by U.S. Public Health Service Grants CA-08748, CA-16889, CA-08415, CA-17085 and AI-12487, and by NCI Contract CB-
- D.H. Schlesinger, G. Goldstein and H.D. Niall, Biochemistry 14, 2214 (1975).
- G. Goldstein, M. P. Scheid, U. Hammerling, E. A. Boyse, D. H. Schlesinger and H.D. Niall, Proc. nat. Acad. Sci. USA 72, 11
- L.T. Hunt and M.O. Dayhoff, BBRC 74, 650 (1977).
- Olson, Biol. Chem. 251, 5901 (1976).
- R.B. Merrifield, J. Am. chem. Soc. 85, 2149 (1963).
- H.T. Keutmann, J.A. Parsons and J.T. Potts, Jr, J. biol. Chem. 245, 1491 (1970).
- K. Komuro and E.A. Boyse, Lancet 1, 740 (1973).
- A. G. Gilman, Proc. nat. Acad. Sci. USA 67, 305 (1970).
- G.W. Tregear, J. van Rietschoten, E. Greene, N.D. Niall, H.T. Keutmann, J.A. Parsons, J.L.H. O'Riordan and T.J. Potts, Jr, Z. Physiol. Chem. 355, 415 (1974).
- G.W. Tregear, in: Peptides, p. 177. Proc. 13th European Peptide Symposium, 1974.
- J.J. Pisano and T.J. Bronzert, J. biol. Chem. 244, 5597 (1969).
- P. Edman, in: Protein Sequence Determination, p.211. Ed. S. Needleman. Springer, New York 1970.
- D.H. Schlesinger and G. Goldstein, Cell 5, 361 (1975).
- D. H. Schlesinger, G. Goldstein, M. P. Scheid and E. A. Boyse, Cell 5, 367 (1975).
- 17 G. Goldstein and D.H. Schlesinger, Lancet 2, 256 (1975).
 18 D.H. Schlesinger and G. Goldstein, Nature 255, 423 (1975).

Inhibition of liver fructose 1,6-bisphosphatase activity by Zn²⁺: Reversal by imidazole pyruvate¹

P.F. Han, G.Y. Han², T.W. Cole, Jr, G.S. Owen and J. Johnson, Jr

Department of Chemistry, Atlanta University, Atlanta (Georgia 30314, USA), 27 December 1977

Summary. Imidazole pyruvate was found to be a very potent natural chelating agent in reversing the inhibition of liver fructose 1,6-bisphosphatase activity by Zn^{2+} . This metabolite may play a physiological role in gluconeogenesis.

The activity of fructose 1,6-bisphosphatase (Fru-P₂ase, EC 3.1.3.11) is markedly activated by a variety of chelating agents³. The basis of this activation is attributed to the chelation of the endogenous Zn^{2+} , a specific and very potent metal inhibitor of Fru-P₂ase^{3,4}. Based on the observations that Zn²⁺ inhibition of Fru-P₂ase activity can be reversed by histidine at concentrations found in rabbit liver under gluconeogenic conditions^{3,5}, it was recently proposed that 'Zn²⁺ and histidine together may act to modulate the levels of Fru-P2ase activity.6. We report here that imidazole pyruvate, which may exist in about the same concentration as histidine in liver cells⁷, is significantly more potent than histidine in reversing the inhibitory effect of Zn²

Materials and methods. Chelex 100 was obtained from Bio-Rad. Imidazole pyruvate, 1-methylhistidine, 3-methylhistidine were purchased from Calbiochem. Other chemicals were obtained from Sigma. Fru-P₂ase was purified from rabbit liver, and assayed at pH 7.5 in the presence of 2.5 mM MgSO₄ as previously described⁸. Whenever chelating agents were added, they were incubated with the enzyme in the assay mixture for 5 min prior to the addition of substrate. Protein concentration was determined spectrophotometrically at 280 nm. A solution containing 1 mg of purified enzyme/ml in 1-cm light path has an absorbance of 0.735.

Results and discussion. As shown in the table, the specific activity (µmoles/min/mg) of the purified enzyme was 3.1 as measured in the routine untreated assay system. It increased to 15.4 when the enzyme was assayed in a system in which all the components of the assay mixture (except




Fig. 1. Effect of various histidine metabolites on the inhibition of Fru-P₂ase activity by Zn²⁺ in a Chelex 100-treated system. Zn²⁺ (1.5 µM) and various histidine metabolites at the indicated concentrations were incubated with the enzyme in the assay mixture for 5 min prior to the addition of substrate. The nomenclature of 1methylhistidine or 3-methylhistidine is based on IUPAC system.

H

$$CH_2$$
 CH_2
 C

Fig. 2. A proposed structure of the chelate complex between Zn²⁺ and histidine (A) or imidazole pyruvate (B). Since Zn^{2+} has a coordination number of 4, 1 molecule of Zn^{2+} may potentially be chelated with 2 molecules of histidine or imidazole pyruvate. The imidazole ring of histidine illustrated in this figure represents the 1-H tautomer which was reported to be more stable than the 3-H tautomer9.

MgSO₄) were treated with Chelex 100 according to the procedure previously described⁴. In the presence of 0.1 mM EDTA, the specific activity further increased to about 19, regardless of whether the assay system was treated or untreated with Chelex 100. This indicates that either the treatment with Chelex 100 failed to completely remove the endogenous Zn2+ or the MgSO4 used was contaminated with a trace amount of Zn^{2+} . The table also shows that in the presence of 1.5 μM Zn^{2+} , the specific activity decreased to less than 1, and this inhibition by Zn²⁺ was completely reversed by 0.1 mM EDTA.

The concentration of histidine in liver cells under fed and fasting conditions were reported to range from 0.2 to 1.0 mM⁵. Within this range we found that imidazole pyruvate was significantly more potent than histidine in reversing the inhibition by Zn²⁺ (figure 1). The minimum concentrations of these 2 compounds required to completely reverse the inhibitory effect of 1.5 μ M Zn²⁺ were approximately 0.4 mM for imidazole pyruvate and 1.2 mM for histidine. This indicates that imidazole pyruvate is superior to histidine in chelating this metal inhibitor. According to White et al.7, a specific aminotransferase is functioning at all times in liver cells for each α -amino acid (with the possible exception of lysine and threonine) and the equilibrium constant for all these transamination reactions is close to 1. This indicates that histidine and imidazole pyruvate are present in about the same amounts in liver cells. Thus, if histidine should be involved in the regulation of gluconeogenesis, as has been suggested^{3,5,6}, imidazole pyruvate might play even a more important role. We found that 1-methylhistidine was nearly as effective as histidine in reversing the inhibitory effect of Zn²⁺, while 3methylhistidine and histamine (the decarboxylated product of histidine) were nearly ineffective (figure 1). These data suggest that the chelation of Zn^{2+} by histidine or imidazole pyruvate involves the carboxylate group and the N-3 of the imidazole ring, as proposed in figure 2.

Specific activity of the purified liver Fru-P₂ase under various assay conditions

Additions**	Treatment of assay system with Chelex 100*	
	Untreated	Treated
None	3.1	15.4
0.1 mM EDTA	19.1	19.2
$0.3 \mu M Zn^{2+}$	1.8	4.1
$1.0 \mu M Zn^{2+}$	0.9	1.3
$1.5 \mu M Zn^{2+}$	0.8	0.8
$1.5 \mu\text{M Zn}^{2+} + 0.1 \text{mM EDTA}$	19.2	19.1

* All the components of the assay mixture (except MgSO₄) were treated with Chelex 100 according to the procedure previously described⁴. ** EDTA or Zn²⁺ was incubated with Fru-P₂ase in the assay mixture for 5 min prior to the addition of substrate.

- This work was supported by grant RR-8006 from the General Research Branch, Division of Research Resources, NIH, USA.
- Present address: Department of Chemistry, Morehouse College, Atlanta (Georgia, USA).
- 3 G.A. Tejwani, F.O. Pedrosa, S. Pontremoli and B.L. Horecker, Proc. nat. Acad. Sci. USA 177, 235 (1976).
- H.G. Nimmo and K.F. Tipton, Biochem. J. 145, 323 (1975).
- 5 S. Pontremoli, E. Melloni, A.D. Flora and B.L. Horecker, Proc. nat. Acad. Sci. USA 71, 2166 (1974).
- F.O. Pedrosa, S. Pontremoli and B.L. Horecker, Proc. nat. Acad. Sci. USA 74, 2742 (1977).
- A. White, P. Handler and E.L. Smith, Principles of Biochemis-
- try, 5th ed., p. 637. McGraw-Hill Co., New York 1973. P.F. Han, V.V. Murthy and J. Johnson, Jr, Archs. Biochem. Biophys. 173, 293 (1976).
- W.F. Reynolds, I.R. Peat, M.H. Freedman and J.R. Lyerla, Jr, J. Am. chem. Soc. 95, 328 (1973).